Skip to main content

'Improved Pharma Demand' Helps Waters' Q4 Sales Surge 17 Percent

NEW YORK (GenomeWeb News) — Waters today said fourth-quarter 2006 revenues increased 17 percent on strong pharma demand as R&D spending rose 17 percent and profit widened 6 percent.
 
Total receipts for the three months ended Dec. 31, 2006, increased to $387 million from $332 million year over year. 
 
CEO Douglas Berthiaume said most of the revenue surge came from “improved pharmaceutical demand, continued growth in our overseas markets, and strong sales growth by our TA instruments division.”
 
Foreign currency translation was responsible for 3 percent of the increased revenue, the company said.
 
R&D spending increased to $19.5 million from $16.7 million year over year.
 
Waters said profits for the quarter grew to $78.9 million from $75.6 million in the year-ago period.
 
Waters said it had around $514.2 million in cash and equivalents as of Dec. 31, 2006.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.